NO961547L - Flavinderivater som anti-virusmidler - Google Patents

Flavinderivater som anti-virusmidler

Info

Publication number
NO961547L
NO961547L NO961547A NO961547A NO961547L NO 961547 L NO961547 L NO 961547L NO 961547 A NO961547 A NO 961547A NO 961547 A NO961547 A NO 961547A NO 961547 L NO961547 L NO 961547L
Authority
NO
Norway
Prior art keywords
viral agents
flavin derivatives
derivatives
flavin
riboflavin
Prior art date
Application number
NO961547A
Other languages
English (en)
Other versions
NO961547D0 (no
Inventor
Washington Odur Ayuko
Original Assignee
Radopath Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Radopath Ltd filed Critical Radopath Ltd
Publication of NO961547D0 publication Critical patent/NO961547D0/no
Publication of NO961547L publication Critical patent/NO961547L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/525—Isoalloxazines, e.g. riboflavins, vitamin B2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

Forskjellige flavinderivat er avdekket til medisinering av pattedyr som et middel mot virus. Riboflavin og riboflavinderivat er gitt som særlige eksempler som kan bli foretrukket.
NO961547A 1993-10-19 1996-04-18 Flavinderivater som anti-virusmidler NO961547L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB939321558A GB9321558D0 (en) 1993-10-19 1993-10-19 Anti-viral agents
PCT/GB1994/002292 WO1995011028A1 (en) 1993-10-19 1994-10-19 Flavin derivatives as anti-viral agents

Publications (2)

Publication Number Publication Date
NO961547D0 NO961547D0 (no) 1996-04-18
NO961547L true NO961547L (no) 1996-06-19

Family

ID=10743784

Family Applications (1)

Application Number Title Priority Date Filing Date
NO961547A NO961547L (no) 1993-10-19 1996-04-18 Flavinderivater som anti-virusmidler

Country Status (26)

Country Link
EP (1) EP0739208A1 (no)
JP (1) JPH09505804A (no)
CN (1) CN1140992A (no)
AP (1) AP620A (no)
AU (1) AU7943794A (no)
BG (1) BG100599A (no)
BR (1) BR9407862A (no)
CA (2) CA2123825A1 (no)
CO (1) CO4520283A1 (no)
CZ (1) CZ113796A3 (no)
EE (1) EE9600057A (no)
GB (2) GB9321558D0 (no)
HR (1) HRP940688A2 (no)
HU (1) HUT76322A (no)
IL (1) IL111338A0 (no)
JO (1) JO1866B1 (no)
MA (1) MA23356A1 (no)
MD (1) MD960168A (no)
NO (1) NO961547L (no)
OA (1) OA10579A (no)
PE (1) PE5596A1 (no)
PL (1) PL314008A1 (no)
SK (1) SK50696A3 (no)
UY (1) UY23844A1 (no)
WO (1) WO1995011028A1 (no)
ZA (1) ZA948191B (no)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH07188052A (ja) * 1993-12-27 1995-07-25 Sanwa Kagaku Kenkyusho Co Ltd インターフェロン用作用効果増強剤及び該増強剤とインターフェロンとを含有する抗ウイルス活性増強組成物
US5756479A (en) * 1994-12-29 1998-05-26 Research Development Foundation Flavin adenine dinucleotide analogue inhibitors of monoamine oxidase
US9044523B2 (en) 2000-06-15 2015-06-02 Terumo Bct, Inc. Reduction of contaminants in blood and blood products using photosensitizers and peak wavelengths of light
US6933285B2 (en) * 2002-05-10 2005-08-23 The Ohio State University Flavin N-oxides: new anti-cancer agents and pathogen eradication agents
ITTO20020622A1 (it) 2002-07-16 2004-01-16 Dayco Europe Srl Gruppo integrato puleggia-smorzatore torsionale
US20060293335A1 (en) * 2002-08-02 2006-12-28 Qishou Xu Riboflavin derivative and its manufacture and uses
EP2545788A1 (de) * 2011-07-13 2013-01-16 Martin Hulliger Diätisches Mehrkomponentensystem
JP2018131410A (ja) * 2017-02-15 2018-08-23 ヒノキ新薬株式会社 カスパーゼ−３阻害剤とその用途
US11497749B2 (en) * 2017-10-24 2022-11-15 Lunella Biotech, Inc. Mitoflavoscins: targeting flavin-containing enzymes eliminates cancer stem cells (CSCS) by inhibiting mitochondrial respiration
CN114126603A (zh) * 2019-07-09 2022-03-01 帝斯曼知识产权资产管理有限公司 用核黄素或dha降低艾拉弗德的病毒活性

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4219545A (en) * 1979-03-23 1980-08-26 Collins Calvin E Treatment of infectious keratoconjunctivitis in animals
US4264601A (en) * 1979-06-12 1981-04-28 The Board Of Regents Of The University Of Oklahoma Antihypertensive agents and their use in treatment of hypertension
US4500524A (en) * 1982-09-15 1985-02-19 Trustees Of Boston University Tranquilizing and reducing or preventing seizures
WO1991002529A2 (en) * 1989-08-14 1991-03-07 John Bennett Kizer Product and method for killing abnormal vertebrate cells
JP2727471B2 (ja) * 1989-09-14 1998-03-11 三井農林株式会社 インフルエンザウィルス感染予防剤
US5192264A (en) * 1989-10-06 1993-03-09 The Beth Israel Hospital Association Methods and apparatus for treating disease states using oxidized lipoproteins
US5217716A (en) * 1990-07-18 1993-06-08 The Beth Israel Hospital Association Method for treating viral infections using oxidized lipoproteins
FR2674753B1 (fr) * 1991-04-02 1995-03-10 Jean Berque Nouvelles indications therapeutiques, en particulier pour le traitement du sida, d'un medicament deja existant et fabrique a partir d'une molecule denuee de contre-indications et d'effets indesirables.
NZ244270A (en) * 1991-09-13 1995-07-26 Eisai Co Ltd Injectable composition comprising riboflavin
WO1993010784A1 (en) * 1991-11-25 1993-06-10 University Of Michigan Therapeutic composition and method for preventing reperfusion injury
JP3073309B2 (ja) * 1992-03-27 2000-08-07 雪印乳業株式会社 シアル酸結合５−デアザフラビン系化合物

Also Published As

Publication number Publication date
CN1140992A (zh) 1997-01-22
MD960168A (ro) 1998-04-30
HUT76322A (en) 1997-08-28
HU9601006D0 (en) 1996-06-28
NO961547D0 (no) 1996-04-18
EE9600057A (et) 1996-10-15
PE5596A1 (es) 1996-04-18
GB9421099D0 (en) 1994-12-07
IL111338A0 (en) 1994-12-29
EP0739208A1 (en) 1996-10-30
AP620A (en) 1997-10-14
SK50696A3 (en) 1997-01-08
CA2174552A1 (en) 1995-04-27
CO4520283A1 (es) 1997-10-15
BR9407862A (pt) 1997-05-20
GB9321558D0 (en) 1993-12-08
ZA948191B (en) 1995-06-08
CZ113796A3 (en) 1996-11-13
BG100599A (en) 1997-02-28
JO1866B1 (en) 1995-12-27
HRP940688A2 (en) 1997-04-30
UY23844A1 (es) 1995-03-28
PL314008A1 (en) 1996-08-05
AU7943794A (en) 1995-05-08
JPH09505804A (ja) 1997-06-10
GB2283913A (en) 1995-05-24
AP9400695A0 (en) 1995-01-31
CA2123825A1 (en) 1995-04-20
WO1995011028A1 (en) 1995-04-27
OA10579A (en) 2002-06-19
MA23356A1 (fr) 1995-07-01

Similar Documents

Publication Publication Date Title
NO20034094D0 (no) Sammensetninger som omfatter et antidiar±middel og et epotilon eller et epotilonderivat
MY107843A (en) Anti-viral compounds.
ES2051641A1 (es) Procedimientos para la preparacion de compuestos derivados de tiourea.
FI891716A (fi) Hiv-proteasinhibitorer, som aer anvaendbara vid behandling av aids.
NO961547L (no) Flavinderivater som anti-virusmidler
DK0711158T3 (da) Metode til behandling af atherosclerose eller restenose ved anvendelse af mikrotubulus-stabiliserende middel
NO304374B1 (no) 1-benzensulfonyl-1,3-dihydro-2H-benzimidazol-2-on-derivater, og farmas°ytiske blandinger som inneholder dem
DK0574457T3 (da) Antiviral nucleosidkombination
HUP9904092A2 (hu) Gyógyszerkészítmény HIV és rák kezelésére valamint eljárás előállítására
DK1126867T3 (da) Sammensætning til forebyggelse og/eller behandling af åreforkalkning
AU3627289A (en) Pharmaceutical products
IT9019324A0 (it) Derivati del bilobalide,loro usi e formulazioni che li contegono
MX9201847A (es) Derivados heterociclicos de antiserotoninas, procedimiento para su preparacion y medicamentos que los contienen.
AU4445089A (en) Lactamimides in the treatment of drug-resistant protozoal infections
AU641279B2 (en) Oligosaccharide derivatives
AU2861389A (en) Disubstituted pyridines
NO954702L (no) Aryldannende medikamenter
NO975636L (no) Farmasöytisk sammensetning for fremming av osteogenese
DK605589D0 (da) Anvendelse af aminobenzocycloalkaner eller syreadditionssalte deraf til fremstilling af et farmaceutikum, saaledes fremstillet praeparat og dettes anvendelse
EP0453247A3 (en) Anti-viral compounds
AU3302389A (en) N-alkylamino derivatives of aromatic, tricyclic compounds in the treatment of drug-resistant protozoal infections
NO912382L (no) Farmasoeytiske kombinasjonspreparater som inneholder cefalosporin- og xantinderivater og deres anvendelse.
ES2195439T3 (es) Glicosidos de antraciclina.
NO933628L (no) Fremgangsmaate og blanding for behandling av Herpes-infeksjoner
DK288989A (da) Cholestadienderivater, deres fremstilling og anvendelse som laegemidler